Background: Gemcitabine/erlotinib treatment offers limited benefit in unselected patients with pancreatic ductal\nadenocarcinoma (PDAC). Development of skin rash has been associated with favorable outcomes in patients\ntreated with gemcitabine/erlotinib. This study aimed to extend knowledge on the effectiveness of gemcitabine/\nerlotinib in metastatic PDAC in the context of clinical practice and with focus on skin rash.\nMethods: This multicenter, non-interventional study enrolled 376 patients with metastatic PDAC receiving\ngemcitabine/erlotinib. The primary endpoint was overall survival (OS) in patients with skin rash versus no skin rash.\nSecondary endpoints included progression-free survival (PFS), treatment satisfaction and safety. All data were\nanalyzed using descriptive statistics. Survival time and time to disease progression were estimated using the Kaplan-\nMeier method. Effectiveness endpoints were analyzed for subgroups by skin rash grade (no rash, rash grade 1, rash.................
Loading....